Stock fact sheet · data as of
Fidelity Advisor Biotechnology Fund Class A (FBTAX): fair value, margin of safety and Wheel Score
Ticker symbol FBTAX · Financial Services · Asset Management · United States · Fund / Note
Is FBTAX undervalued?
At 49.07 (close of 5 Nov 2026), FBTAX trades 76% over the GLS average fair value of 27.82, with 1 of 3 models above the price. The stock earns none of the Wheel Score's Value points at this price. That is a statement about price against trailing fundamentals, not about the company's prospects - the Wall Street View and the Growth tab on the Quote page carry the forward numbers.
The average is built from just 3 models (DCF, 10 Cap, DDM) - the rest returned nothing because an input they need (dividends, free cash flow, book value) is zero or negative - so treat it with more caution than usual.
FBTAX looks like a fund, note or preferred share rather than an operating company, so the nightly engine files it under Fund / Note: the valuation models are not built for it, and its Wheel Score is capped at 45.
Nine valuation models for FBTAX
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 54.62 | +11% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | 20.83 | -58% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | 8.00 | -84% | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | -0.3011 | -101% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Fidelity Advisor Biotechnology Fund Class A scores 8 of 9 on the Piotroski F-score, the nine yes/no tests of profitability, leverage and efficiency on the latest annual accounts - a strong reading that passes the "Piotroski 6 or more" Wheel Trade Filter with room to spare. There is no GLS Moat score for FBTAX: funds, notes and second share lines get none, and so does a company with fewer than two years of accounts on file. The Moat part of the Wheel Score is zero.
Returns on capital are high - ROIC 28.2%, ROE 40.7%, ROA 19.4% - with debt at 0.44 times equity and a free-cash-flow yield of 1.9%.
The dividend yield is 1.11% with a payout ratio of 42% - a small yield that leaves most of the earnings in the business.
Institutional ownership scores 5/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 8 / 9 | ROIC | 28.2% |
|---|---|---|---|
| GLS Moat | - / 10 | ROE | 40.7% |
| Debt / equity | 0.44 | ROA | 19.4% |
| Free-cash-flow yield | 1.9% | Payout ratio | 42% |
| Institutions | 5 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 16: No options
No options are listed on Fidelity Advisor Biotechnology Fund Class A in our nightly snapshot, so it fails the first Wheel Trade Filter (options that actually trade) (it reads 16, under 70) and is left out of every options scan; the fair value and health figures above are still useful for a plain stock position.
Volume runs at - a day on a market cap of $2.4B, with a beta of 0.62 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score rates that fair.
| Filter | Wheel Trade Filter | Result | Detail |
|---|---|---|---|
| 1 | Options that actually trade | Fails | no listed options |
| 2 | A real business, not a gamble | Fails | a fund or note, not a company |
| 3 | Below fair value | Fails | trades 76% above our fair value |
| 4 | Financially healthy | Passes | Piotroski F-score 6 or more out of 9 (a company with no score on file passes) |
| 5 | Can repay its debt | Passes | Long-term debt repaid from 3 years of operating cash flow or less (6 for real estate and utilities; banks and insurers are not judged on it) |
| 6 | No serious red flags | Passes | Red Flags score 60 or more out of 100 (earnings, margins, debt, analysts, filings and price checked the same way for every stock) |
| 7 | A premium worth selling | Fails | no implied volatility |
| 8 | Big enough | Passes | Market cap $1 billion or more |
| 9 | Not a penny stock | Passes | Share price $5 or more |
| How it ranks | Rating | From | |
|---|---|---|---|
| Value | Weak | 76% above fair value | |
| Premium | Weak | no option data | |
| Moat | Weak | no moat score | |
| Health | Strong | Piotroski 8/9 | |
| Red Flags | Fair | not scored yet - half marks | |
| Option trading | Weak | no option volume data | |
| Stability | Fair | beta 0.62, $2.4B company |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls: a stock must pass all 9 Wheel Trade Filters to score 70, and the score then ranks the ones that pass; the Sunday Scan is the top 10. It is updated nightly and is not a recommendation. How the Wheel Score works · the walkthrough lesson shows how it fits into a trade, start to finish.
Upcoming events
No upcoming earnings date is recorded for FBTAX in the nightly calendar.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Asset Management
The 12 companies below are the closest to Fidelity Advisor Biotechnology Fund Class A by market cap within the Asset Management industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| OXLCM Oxford Lane Capital Corp. | 24.80 | 70.18 | +65% | 27No options | $2.4B |
| KLMN Invesco Exchange-Traded Fund Trust II - Invesco MSCI North America Climate ETF | 31.42 | 2.83 | -1009% | 10No options | $2.5B |
| CEMDX Cullen Emerging Markets High Dividend Fd Retail Cl | 17.91 | 447.82 | +96% | 25No options | $2.4B |
| NVG Nuveen AMT-Free Municipal Credit Income Fund | 11.52 | 18.09 | +36% | 27No options | $2.5B |
| ABXL Abacus Global Management, Inc. - 9.875% Fixed Rate Senior Notes due 2028 | 25.44 | 20.58 | -24% | 9No options | $2.5B |
| CHCLX AB Discovery Growth Fund, Inc. - Class A | 11.29 | 9.61 | -17% | 11No options | $2.5B |
| ASST Strive, Inc. | 22.92 | - | - | 22Weak | $2.5B |
| GDV The Gabelli Dividend & Income Trust | 29.20 | 122.89 | +76% | 33No options | $2.5B |
| BDOAX iShares MSCI Total International Index Fund - Class A | 13.85 | - | - | 14No options | $2.5B |
| KYN Kayne Anderson Energy Infrastructure Fund Inc. | 13.66 | 40.04 | +66% | 37Weak | $2.3B |
| UTF Cohen & Steers Infrastructure Fund, Inc | 26.41 | 81.62 | +68% | 27No options | $2.6B |
| CIPMX Champlain Mid Cap Fund Advisor Class | 21.69 | - | - | 14No options | $2.3B |
⚖ Compare FBTAX with 7 of them All Financial Services stocks →
Scan the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the top 10 stocks that pass all 9 Wheel Trade Filters, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about FBTAX
Is FBTAX undervalued right now?
No: at 49.07 the stock trades 76% above the GLS average fair value of 27.82 (data as of 5 Nov 2026), well beyond what trailing earnings, cash flow and book value support.
What is the Wheel Score of FBTAX and what does it mean?
FBTAX has no listed options in our nightly snapshot, so it cannot be wheeled; it fails the first Wheel Trade Filter (options that actually trade), stays under 70 and is shown as "No options".
What is the GLS fair value for FBTAX?
27.82 per share as of 5 Nov 2026 - the simple average of the 3 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Fidelity Advisor Biotechnology Fund Class A report earnings next?
No upcoming earnings date is recorded for FBTAX in our calendar as of 5 Nov 2026; the Calendars page is refreshed every morning.
Does FBTAX have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on FBTAX, so the wheel strategy cannot be run on it and the Wheel Score stays under 70.